Drugs / VVN001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04556838 | Dec 2020 → Dec 2021 | dry eye syndrome | VivaVision Biotech, Inc | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06360133 | Apr 2024 → Mar 2026 overdue | dry eye syndrome | VivaVision Biotech, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VVN001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04556838 ↗ |
| Known as | VVN001 Ophthalmic Solution | “VVN001 Ophthalmic Solution (VVN001), a small-molecule antagonist” PMID 36586669 ↗ Dec 2022 |
| Action | Inhibit | “a small-molecule antagonist of lymphocyte function-associated antigen-1 (LFA-1)” PMID 36586669 ↗ Dec 2022 |
| Modality | Small molecule | “a small-molecule antagonist” PMID 36586669 ↗ Dec 2022 |